357 filings
Page 5 of 18
8-K
w7awly0n
26 Nov 18
ImmunoGen Announces Resignation of Chief Financial Officer
4:15pm
8-K
zxq986ff9q1h1lnee8b
2 Nov 18
ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results
6:36am
8-K
5zalhtrgadhifbd
27 Jul 18
ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
6:35am
8-K
z0c3lvn0
28 Jun 18
Entry into a Material Definitive Agreement
4:05pm
8-K
z8eal6t59z z5hry1gl
22 Jun 18
Departure of Directors or Certain Officers
4:02pm
8-K
d4g5d1baq047m 3iewb4
21 Jun 18
ImmunoGen Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
8:27am
8-K
mdm8 tqwen2rmq8gq8m9
11 Jun 18
ImmunoGen Announces Closing of Public Offering of Common Stock
4:13pm
8-K
bc43rj
7 Jun 18
Entry into a Material Definitive Agreement
4:35pm
8-K
dxnm2
17 May 18
Data from Avastin Cohort to be Presented at 2018 ASCO Annual Meeting
7:50am
8-K
bw13k
4 May 18
ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
6:36am
8-K
fade e8x4sp35
26 Apr 18
FORWARD I trial has completed full enrolloment; top-line results expected in the first half of 2019
12:00am
8-K
mg9vfm1h
9 Apr 18
Entry into a Material Definitive Agreement
12:00am
8-K
2909kknr71h
30 Mar 18
Entry into a Material Definitive Agreement
12:00am
8-K
atww47 xth5d
20 Feb 18
Departure of Directors or Certain Officers
12:00am
8-K
872aom6 zgq
9 Feb 18
ImmunoGen Reports Pipeline Progress and 2017 Operating Results
12:00am
8-K
1fkvfrpl90j7bf
8 Feb 18
Cost Associated with Exit or Disposal Activities
12:00am
8-K
xvpioqhv
24 Jan 18
ImmunoGen Appoints Stuart A. Arbuckle to Board of Directors
12:00am
8-K
r2zx07q4m5
8 Jan 18
Results of Operations and Financial Condition
12:00am
8-K
2sn8f8 bjjrymt
3 Nov 17
ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
12:00am
8-K
odujht6 83t9vud
11 Oct 17
Immunogen Announces Closing of Public Offering
12:00am